^




    Show legend
    Group by Gene:
    Include preclinical:

    BTK inhibitor
    ibrutinib
    zanubrutinib
    pirtobrutinib
    		0
    BTK inhibitor
    orelabrutinib
    acalabrutinib
    M7583
    TG-1701
    JNJ-4681
    CD20 inhibitor
    rituximab
    obinutuzumab
    Rixathon (rituximab biosimilar)
    		1
    CD20 inhibitor
    rituximab-pvvr
    rituximab-abbs
    rituximab / hyaluronidase
    rituximab + obinutuzumab
    ofatumumab
    rituximab-arrx
    CD19-targeted CAR-T immunotherapy
    lisocabtagene maraleucel
    axicabtagene ciloleucel
    tisagenlecleucel-T
    brexucabtagene autoleucel
    CB-010
    		2
    CD19-targeted CAR-T immunotherapy
    CTX110
    ALLO-501A
    relmacabtagene autoleucel
    PZ01
    JCAR014
    ISIKOK-19
    ARI-0001
    pembrolizumab
    nivolumab
    		3
    PD1 inhibitor
    zimberelimab
    penpulimab
    sintilimab
    geptanolimab
    fludarabine oral
    cisplatin
    		4
    DNA synthesis inhibitor
    temozolomide
    gemcitabine
    nelarabine
    fludarabine IV
    5
    PI3Kδ inhibitor
    idelalisib
    INCB50465
    6
    Bcl2 inhibitor, CD20 inhibitor
    venetoclax + obinutuzumab
    venetoclax + rituximab
    7
    CD52 inhibitor
    alemtuzumab
    chlorambucil
    		8
    Alkylating agent
    bendamustine RTD
    cyclophosphamide
    9
    THF dehydrogenase inhibitor, Dihydrofolic acid reductase inhibitor
    methotrexate
    belinostat
    		10
    HDAC inhibitor
    romidepsin
    vorinostat
    CG-781
    11
    Proteasome inhibitor, CD20 inhibitor
    rituximab + ixazomib
    rituximab + bortezomib
    CD20 inhibitor + zanubrutinib
    obinutuzumab + acalabrutinib
    ibrutinib + rituximab
    		12
    BTK inhibitor, CD20 inhibitor
    ibrutinib + obinutuzumab
    rituximab + zanubrutinib
    obinutuzumab + zanubrutinib
    rituximab + acalabrutinib
    rituximab + orelabrutinib
    13
    Topoisomerase II inhibitor
    pixantrone
    etoposide IV
    14
    PI3Kδ inhibitor, CD20 inhibitor
    rituximab + idelalisib
    obinutuzumab + INCB50465
    pembrolizumab + ibrutinib
    		15
    PD1 inhibitor, BTK inhibitor
    nivolumab + ibrutinib
    tislelizumab + zanubrutinib
    16
    CD52 inhibitor, CD20 inhibitor
    rituximab + alemtuzumab
    17
    mTOR inhibitor
    everolimus
    temsirolimus
    ceritinib
    		18
    ALK inhibitor
    crizotinib
    alectinib
    19
    Bcl2 inhibitor
    venetoclax
    APG-2575
    20
    Bcl2 inhibitor, BTK inhibitor
    venetoclax + ibrutinib
    ibrutinib + APG-2575
    21
    PIK3CA inhibitor, PI3Kδ inhibitor
    copanlisib
    PD-L1 inhibitor
    sugemalimab
    		22
    PD-L1 inhibitor
    avelumab
    atezolizumab
    durvalumab
    loncastuximab tesirine-lpyl
    		23
    DNA replication inhibitor, CD19-targeted antibody-drug conjugate
    SGN-CD19B
    IKS03
    24
    CCR4 receptor antagonist
    mogamulizumab-kpkc
    FLX475
    25
    IL-2 stimulant
    denileukin diftitox
    tazemetostat
    		26
    EZH2 inhibitor
    CPI-169
    SHR-2554
    27
    Proteasome inhibitor
    bortezomib
    carfilzomib
    28
    Purinergic receptor P1 agonist
    cladribine
    29
    DNA replication inhibitor
    bendamustine
    30
    XPO1 inhibitor
    selinexor
    31
    Retinoid X receptor modulator
    bexarotene oral
    32
    Protein synthesis inhibitor, Asparagine depleter
    recombinant Erwinia asparaginase
    33
    THF dehydrogenase inhibitor
    pralatrexate
    34
    DNA synthesis inhibitor, DNA-directed DNAP inhibitor
    cytarabine
    35
    Tubulin inhibitor
    vinblastine
    36
    CXCL12 inhibitor, Farnesyl transferase inhibitor
    tipifarnib
    37
    DNMT inhibitor
    azacitidine oral
    38
    PIK3CA inhibitor, PI3Kδ inhibitor, CD20 inhibitor
    rituximab + copanlisib
    39
    PD1 inhibitor, LAG-3 inhibitor
    MGD013
    40
    STAT3 protein degrader
    KT-333
    41
    CDK9 inhibitor
    SLS009
    42
    NK cell stimulant
    IDP-023
    43
    PD1 inhibitor, Survivin inhibitor
    pembrolizumab + MVP-S
    44
    CD38 inhibitor
    daratumumab
    45
    SETD2 inhibitor
    IPN60210
    46
    JAK1 inhibitor
    DZD4205
    47
    CXCR4 antagonist, BTK inhibitor
    ibrutinib + X4P-001
    ibrutinib + BMS-936564
    48
    CD19-targeted CAR-T immunotherapy, BTK inhibitor
    ibrutinib + lisocabtagene maraleucel
    acalabrutinib + axicabtagene ciloleucel
    49
    Bcl2 inhibitor, BTK inhibitor, CD20 inhibitor
    venetoclax + obinutuzumab + zanubrutinib
    venetoclax + ibrutinib + rituximab
    50
    CD38 inhibitor, IL-15R agonist
    daratumumab + NKTR-255
    51
    MEK inhibitor, BRAF inhibitor
    trametinib + dabrafenib
    CD30-targeted CAR-T immunotherapy
    		52
    CD30-targeted CAR-T immunotherapy
    TT11
    CART-30
    BET inhibitor
    		53
    BET inhibitor
    RG6146
    INCB57643
    54
    CD47 inhibitor, CD20 inhibitor
    IMM0306
    rituximab + ALX148
    55
    PARP inhibitor
    fluzoparib
    olaparib
    56
    CXCR4 antagonist
    X4P-001
    57
    CD20-targeted CAR-T immunotherapy
    MB-106
    58
    CD3 agonist, ROR1 inhibitor
    NVG-111
    59
    ROR1 inhibitor, BTK inhibitor
    ibrutinib + UC-961
    60
    CD19-targeted CAR-T immunotherapy, BCMA-targeted CAR-T immunotherapy
    GC012F
    61
    CD70 inhibitor
    ARGX-110
    62
    PD1 inhibitor, CD19-targeted CAR-T immunotherapy
    BRL-201
    63
    BRAF inhibitor
    dabrafenib
    64
    MEK inhibitor
    trametinib
    65
    SIRPA antagonist, CD20 inhibitor
    rituximab + BMS-986351
    66
    MDM2 inhibitor, BTK inhibitor
    acalabrutinib + KRT-232
    67
    FGFR inhibitor
    pemigatinib
    68
    Protein synthesis inhibitor, CD22-targeted cytotoxin
    moxetumomab pasudotox
    69
    Cereblon modulator, Pleiotropic pathway modifier, CD20 inhibitor
    rituximab + CC-122
    70
    Topoisomerase II inhibitor, DNA synthesis inhibitor
    gemcitabine + doxorubicin hydrochloride
    71
    CD137 agonist, CD20 inhibitor
    rituximab + PF-05082566
    72
    Cereblon modulator, Pleiotropic pathway modifier
    CC-122
    EPOCH-R
    R-CVP
    R-CHOP
    R-CVAD
    R-GDP
    RICE
    RIVAC
    PCR
    FCR
    VR-CAP
    R-DHAP
    R-DHAX
    R-GemOx
    G-CHOP
    MINE
    GemOx
    ESHAP
    ICE
    GDP
    DHAX
    DHAP
    CEOP
    CEPP
    R-ESHAP
    R-GCVP
    R-CEOP
    R-CEPP
    R-CDOP
    O-CVP
    OFAR
    BR
    IRd
    BDR
    CaRD
    RCD
    RCP
    CYVE
    TBC
    		73
    Chemotherapy
    R-MPV
    MT
    BEACOPP
    EPOCH
    Bv-AVE-PC
    GVD
    IGEV
    EPIC
    TBC + CYVE
    MATRix
    CHOEP
    AEPA-CAPDAC
    CVbP
    P-GEMOX
    AspaMetDex
    DDGP
    SMILE
    CHOP
    OEPA
    ABVE-PC
    Pola-R-CHP
    R-Maxi-CHOP
    R-CHOP + R-DHAP
    R-DHAX + R-CHOP
    R-DHAC + R-CHOP
    GELAD
    L / P-VIPD
    ViPOR
    BV-ICE
    ABVD
    CARMEN
    C-RICE
    CHEP-BV
    CMOP
    ZPR
    BOVen
    CVAD
    CEOP-E
    R-BV-CHP
    DICE
    74
    CAR-T immunotherapy
    CAR-T immunotherapy
    75
    T-lymphocyte cell therapy
    T-lymphocyte cell therapy
    76
    CD22-targeted CAR-T immunotherapy, CD19-targeted CAR-T immunotherapy
    CD19-targeted CAR-T immunotherapy + CD22-targeted CAR-T immunotherapy
    CAR-T19 / CAR-T22 immunotherapy
    77
    Aurora kinase inhibitor
    Aurora kinase inhibitor
    78
    Immunotherapy
    Immunotherapy
    79
    Tyrosine kinase inhibitor
    Tyrosine kinase inhibitor
    80
    EED inhibitor
    EED inhibitor
    81
    USP47 inhibitor
    USP47 inhibitor
    82
    PRC2 inhibitor
    PRC2 inhibitor
    83
    CD20 inhibitor, Chemotherapy
    CODOX-M + rituximab
    84
    BTK inhibitor, Chemotherapy
    BR + ibrutinib
    85
    TNFα inhibitor, IL-12 inhibitor, IL-6 inhibitor
    lenalidomide
    86
    TNFα inhibitor, Immunotherapy, IL-12 inhibitor, IL-6 inhibitor
    Immunotherapy + lenalidomide
    87
    PI3Kδ inhibitor, Chemotherapy
    BR + idelalisib
    88
    THF dehydrogenase inhibitor, Dihydrofolic acid reductase inhibitor, Chemotherapy
    RICE + methotrexate
    RIVAC + methotrexate
    89
    PI3Kγ inhibitor, PI3Kδ inhibitor
    duvelisib
    90
    TNFα inhibitor, IL-12 inhibitor, IL-6 inhibitor, CD20 inhibitor
    rituximab + lenalidomide
    lenalidomide + obinutuzumab
    91
    CD30-targeted antibody-drug conjugate, PD1 inhibitor, Microtubule inhibitor
    nivolumab + brentuximab vedotin
    brentuximab vedotin
    		92
    CD30-targeted antibody-drug conjugate, Microtubule inhibitor
    McSAF 02
    TEQ102
    93
    CD20-targeted CAR-T immunotherapy, Bcl2 inhibitor
    CD20-targeted CAR-T immunotherapy + venetoclax
    valemetostat
    		94
    EZH1 inhibitor, EZH2 inhibitor
    HM97594
    DW91170
    95
    TNFα inhibitor, IL-12 inhibitor, IL-6 inhibitor, BTK inhibitor, CD20 inhibitor
    ibrutinib + rituximab + lenalidomide
    rituximab + lenalidomide + acalabrutinib
    epcoritamab-bysp
    mosunetuzumab-axgb
    		96
    CD3 agonist, CD20 inhibitor
    glofitamab-gxbm
    EX103
    REGN1979
    97
    TNFα inhibitor, IL-1β inhibitor, IL-10 stimulant, NK cell stimulant, IL-6 inhibitor
    pomalidomide
    98
    JAK1 inhibitor, JAK2 inhibitor
    ruxolitinib
    99
    Proteasome inhibitor, Chemotherapy
    R-CHOP + bortezomib
    100
    ROS1 inhibitor, ALK inhibitor
    lorlatinib
    101
    Tubulin polymerization promoter, DNA synthesis inhibitor
    carboplatin + gemcitabine
    102
    Topoisomerase II inhibitor, Alkylating agent
    cyclophosphamide + etoposide IV
    103
    ALK inhibitor, EGFR inhibitor
    brigatinib
    104
    Topoisomerase II inhibitor, Tubulin polymerization promoter, DNA inhibitor, DNA replication inhibitor
    carboplatin + etoposide oral + bendamustine
    105
    THF dehydrogenase inhibitor, Alkylating agent, DNA synthesis inhibitor, Dihydrofolic acid reductase inhibitor, DNA-directed DNAP inhibitor
    cytarabine + methotrexate + thiotepa
    106
    Alkylating agent, DNA synthesis inhibitor, DNA-directed DNAP inhibitor
    cytarabine + thiotepa
    107
    THF dehydrogenase inhibitor, DNA synthesis inhibitor, Dihydrofolic acid reductase inhibitor, DNA-directed DNAP inhibitor
    cytarabine + methotrexate
    108
    THF dehydrogenase inhibitor, Thymidylate synthase inhibitor
    pemetrexed
    109
    Ionizing radiation emitter, CD20 inhibitor
    ibritumomab tiuxetan
    rituximab + ibritumomab tiuxetan
    110
    Alkylating agent, DNA synthesis inhibitor
    carmustine
    111
    Tubulin polymerization promoter, DNA synthesis inhibitor, CD20 inhibitor
    carboplatin + gemcitabine + rituximab
    112
    Tubulin polymerization promoter, DNA synthesis inhibitor, DNA-directed DNAP inhibitor
    carboplatin + cytarabine
    113
    PDGFR antagonist, mutant c-KIT inhibitor, CSF-1R inhibitor
    avapritinib
    114
    Casein kinase I epsilon inhibitor, PI3Kδ inhibitor
    umbralisib
    115
    CD79b-targeted antibody-drug conjugate, Microtubule inhibitor
    polatuzumab vedotin-piiq
    ARC-02
    116
    TNFα inhibitor, CD19 inhibitor, IL-12 inhibitor, IL-6 inhibitor
    lenalidomide + tafasitamab-cxix
    117
    CD79b-targeted antibody-drug conjugate, Microtubule inhibitor, CD20 inhibitor
    rituximab + polatuzumab vedotin-piiq
    118
    THF dehydrogenase inhibitor, DNA synthesis inhibitor, Dihydrofolic acid reductase inhibitor, DNA-directed DNAP inhibitor, Chemotherapy
    R-CVAD + cytarabine + methotrexate
    119
    HDAC inhibitor, MAPK inhibitor, HDAC10 inhibitor, HDAC1 inhibitor, PI3K inhibitor, HDAC2 inhibitor, AKT inhibitor, HDAC3 inhibitor
    chidamide
    120
    DNMT inhibitor, Chemotherapy
    CHOP + azacitidine oral
    121
    PDGFR inhibitor, Bcr-abl tyrosine kinase inhibitor, c-KIT inhibitor
    imatinib
    122
    CD22-targeted antibody-drug conjugate, DNA replication inhibitor
    inotuzumab ozogamicin
    123
    CD20-targeted CAR-T immunotherapy, CD19-targeted CAR-T immunotherapy
    JNJ-4496
    IMPT-314
    124
    CD16 agonist, NK cell stimulant
    FT516
    125
    HDAC inhibitor, DNA methylation inhibitor
    azacitidine + romidepsin
    126
    CD30 inhibitor, NK cell stimulant, CD16A agonist
    AFM13 / AB-101
    127
    Ionizing radiation emitter, DNA inhibitor
    CLR 131
    128
    SIK3 inhibitor, PI3K inhibitor, PI3Kγ inhibitor, PI3Kδ inhibitor
    RP6530
    129
    Bcr-abl tyrosine kinase inhibitor, Src kinase inhibitor, c-KIT inhibitor, PDGFR β antagonist, EphA2 receptor antagonist
    dasatinib
    130
    PD-L1 inhibitor, Bcl2 inhibitor, CD20 inhibitor
    venetoclax + atezolizumab + obinutuzumab
    131
    TNFα inhibitor, IL-12 inhibitor, IL-6 inhibitor, BTK inhibitor
    lenalidomide + zanubrutinib
    132
    CD30 inhibitor, CD16A agonist
    AFM13
    133
    CD19 inhibitor, CD3 agonist
    A-319
    CLN-978
    134
    TNFα inhibitor, IL-12 inhibitor, CD30-targeted antibody-drug conjugate, IL-6 inhibitor, Microtubule inhibitor, CD20 inhibitor
    rituximab + lenalidomide + brentuximab vedotin
    135
    CD38 inhibitor, PD1 inhibitor
    cemiplimab-rwlc + isatuximab-irfc
    136
    TNFα inhibitor, IL-12 inhibitor, CD3 agonist, IL-6 inhibitor, CD20 inhibitor
    rituximab + lenalidomide + epcoritamab-bysp
    lenalidomide + epcoritamab-bysp
    137
    Bcl2 inhibitor, Tubulin inhibitor, CD20 inhibitor
    AR160
    138
    TNFα inhibitor, IL-12 inhibitor, PD1 inhibitor, IL-6 inhibitor, CD20 inhibitor
    rituximab + lenalidomide + penpulimab
    139
    MDMX inhibitor, MDM2 inhibitor
    ALRN-6924
    140
    CD20-targeted CAR-T immunotherapy, γδ TCR modulator
    ADI-001
    141
    CD20-targeted antibody-drug conjugate, Microtubule inhibitor
    MRG001
    142
    TNFα inhibitor, IL-12 inhibitor, IL-6 inhibitor, Bcl2 inhibitor, CD20 inhibitor
    venetoclax + rituximab + lenalidomide
    143
    c-MET inhibitor, ROS1 inhibitor, ALK inhibitor
    TQ-B3101
    144
    CD37-targeted antibody-drug conjugate, Microtubule inhibitor
    AGS67E
    145
    PD1 inhibitor, IDO1 inhibitor
    nivolumab + BMS-986205
    146
    HDAC inhibitor, MAPK inhibitor, HDAC10 inhibitor, HDAC1 inhibitor, PD1 inhibitor, PI3K inhibitor, HDAC2 inhibitor, AKT inhibitor, HDAC3 inhibitor
    sintilimab + chidamide
    147
    Bifunctional alkylating agent, THF dehydrogenase inhibitor, Topoisomerase II inhibitor, DNA synthesis inhibitor, Dihydrofolic acid reductase inhibitor, DNA-directed DNAP inhibitor
    cytarabine + ifosfamide + etoposide IV + methotrexate
    148
    IL-15R agonist, CD20 inhibitor
    rituximab + NKTR-255
    NKTR-255 + Ritucad (rituximab biosimilar)
    149
    CD79b-targeted antibody-drug conjugate, Microtubule inhibitor, Bcl2 inhibitor
    venetoclax + polatuzumab vedotin-piiq
    150
    CD30-targeted antibody-drug conjugate, Microtubule inhibitor, CD20 inhibitor
    rituximab + brentuximab vedotin
    151
    TNFα inhibitor, PD-L1 inhibitor, IL-12 inhibitor, IL-6 inhibitor
    durvalumab + lenalidomide
    152
    HDAC inhibitor, PI3K inhibitor
    CUDC-907
    153
    ALK inhibitor, PP2A inhibitor
    crizotinib + LB-100
    154
    EIF-2 kinase modulator
    BTM-3566
    155
    CD3 agonist, DNA replication inhibitor, CD20 inhibitor, CD19-targeted antibody-drug conjugate
    loncastuximab tesirine-lpyl + IGM-2323
    156
    HDAC1 inhibitor, HDAC2b inhibitor
    purinostat
    157
    CD22-targeted antibody-drug conjugate, Microtubule inhibitor
    TRPH-222
    158
    P21-activated kinase inhibitor
    FRAX597 + PF-3758309
    159
    CD38-targeted antibody-drug conjugate, Ionizing radiation emitter
    Actinium-225 conjugated to daratumumab
    160
    CD30-targeted antibody-drug conjugate, Microtubule inhibitor, Topoisomerase I inhibitor
    brentuximab vedotin + SGN-CD30C
    161
    CXCR5-targeted antibody-drug conjugate, KIF11 inhibitor
    VIP924
    162
    SLC1A5-targeted antibody-drug conjugate, DNA replication inhibitor
    MEDI7247
    163
    DNA replication inhibitor, CD25-targeted antibody-drug conjugate
    ADCT-301
    164
    CCR7-targeted antibody-drug conjugate, Microtubule inhibitor
    JBH492
    165
    CD352-targeted antibody-drug conjugate, DNA replication inhibitor
    SGN-CD352A
    166
    BCMA-targeted antibody-drug conjugate, Microtubule inhibitor
    belantamab mafodotin-blmf
    167
    Alkylating agent, DNA repair enzyme inhibitor
    LP-284
    168
    CD30-targeted antibody-drug conjugate, Topoisomerase I inhibitor
    SGN-35C
    169
    CD38 inhibitor, CD3 agonist, CD28 agonist
    SAR442257
    170
    CD19 inhibitor, CD16A inhibitor, IL-15R stimulant, CD20 inhibitor
    rituximab + FT596
    171
    Topoisomerase II inhibitor, HDAC inhibitor, MAPK inhibitor, HDAC10 inhibitor, HDAC1 inhibitor, PI3K inhibitor, HDAC2 inhibitor, AKT inhibitor, HDAC3 inhibitor
    doxorubicin hydrochloride + chidamide
    172
    Electron transport complex I inhibitor
    IACS-010759
    173
    Bcl2 inhibitor, SYK inhibitor
    venetoclax + fostamatinib
    174
    Histone acetyltransferase activator
    YF2
    175
    PIK3CA inhibitor, Bcl2 inhibitor, PI3Kδ inhibitor
    venetoclax + copanlisib
    176
    PLK1 inhibitor
    NBL-001
    177
    Apoptosis stimulant
    arsenic trioxide
    178
    CD123-targeted antibody-drug conjugate, KIF11 inhibitor
    VIP943
    179
    miR-155 inhibitor
    MRG-106
    180
    Bcl2 inhibitor, Bcl-xL inhibitor, Bcl-w inhibitor
    ABT 263
    181
    ROR1-targeted antibody-drug conjugate, Microtubule inhibitor
    MK-2140
    182
    MYC inhibitor
    GT19077
    183
    MALT1 protein inhibitor
    ONO-7018
    JNJ-6633
    184
    Lymphoid kinome inhibitor, Myeloid kinome inhibitor, BTK inhibitor, FLT3 inhibitor
    CG-806
    185
    MDM2 inhibitor, Bcl2 inhibitor
    APG-115 + APG-2575
    186
    PDK1 inhibitor, Bcl2 inhibitor
    venetoclax + VRx-510
    187
    Casein kinase I epsilon inhibitor, PI3Kδ inhibitor, BTK inhibitor, CD20 inhibitor
    umbralisib + ublituximab-xiiy + TG-1701
    188
    BET inhibitor, EZH2 inhibitor
    CPI-169 + CPI-203
    189
    Kinase inhibitor
    EUD-GK-001
    190
    Lymphoid kinome inhibitor, Bcl2 inhibitor, Myeloid kinome inhibitor, BTK inhibitor, FLT3 inhibitor
    venetoclax + CG-806
    191
    BTK degrader
    ABBV-101
    192
    ACVR1 inhibitor, IRAK-1 inhibitor, CSF-1R inhibitor, JAK2 inhibitor, FLT3 inhibitor
    pacritinib
    193
    PIM inhibitor, Bcl2 inhibitor, BTK inhibitor
    venetoclax + ibrutinib + AZD1208
    194
    PLK4 inhibitor
    CFI-400945
    195
    PLK1 inhibitor, PIK3CA inhibitor, PI3Kδ inhibitor
    copanlisib + NBL-001
    196
    EZH2 inhibitor, Bcl2 inhibitor
    venetoclax + tazemetostat
    197
    Multi-tyrosine kinase inhibitor
    gilteritinib
    198
    MCL1 inhibitor
    S63845
    199
    MCL1 inhibitor, Bcl2 inhibitor
    venetoclax + S63845
    200
    CD52 inhibitor, BTK inhibitor
    ibrutinib + alemtuzumab
    201
    CDK4 inhibitor, CDK6 inhibitor
    palbociclib
    202
    HSP90 inhibitor
    AUY922
    203
    LRRK2 inhibitor, ALK inhibitor
    TAE-684
    204
    γ-secretase inhibitor
    Compound E
    205
    Menin-MLL inhibitor
    MI-2
    206
    MALT1 protein inhibitor, BTK inhibitor
    JNJ-6633 + JNJ-4681
    207
    DNA replication inhibitor, CD70-targeted antibody-drug conjugate
    SGN-CD70A
    208
    XPO1 inhibitor, Bcl2 inhibitor
    venetoclax + selinexor
    209
    Protein complex 1 inhibitor
    IM156
    210
    AMPK activator, mTOR inhibitor
    phenformin
    211
    IKZF1 degrader, IKZF3 degrader
    CFT7455
    212
    IKZF1 degrader, IKZF3 degrader, IRAK-4 degrader, CD20 inhibitor
    rituximab + KT-413
    213
    ERK2 inhibitor, ERK1 inhibitor
    ASN007
    214
    MEK inhibitor, ALK inhibitor
    trametinib + crizotinib
    215
    HDAC inhibitor, EZH2 inhibitor, MAPK inhibitor, HDAC10 inhibitor, HDAC1 inhibitor, PI3K inhibitor, HDAC2 inhibitor, AKT inhibitor, HDAC3 inhibitor
    chidamide + SHR-2554
    216
    BRD4 inhibitor, PI3K inhibitor, BTK inhibitor
    SRX3262
    217
    MEK inhibitor, Bcl2 inhibitor
    venetoclax + trametinib
    218
    PIKfyve inhibitor, Tubulin inhibitor
    HZX-02-059
    219
    ROR1-targeted CAR-T immunotherapy
    ONCT-808
    220
    DHODH inhibitor, Bcl2 inhibitor
    venetoclax + DUP 785
    221
    NRF2 inhibitor
    brusatol
    222
    XIAP antagonist, cIAP1 antagonist, cIAP2 antagonist
    ASTX660
    223
    NK cell stimulant, CD20 inhibitor
    IPH6501
    224
    PI3Kγ inhibitor, DNA PK inhibitor, Bcl2 inhibitor, PI3Kδ inhibitor
    venetoclax + BR101801
    225
    DNA polymerase theta inhibitor
    VP-006
    ART558
    226
    IKZF1 degrader, IKZF3 degrader, IRAK-4 degrader, BTK inhibitor
    BTK inhibitor + KT-413
    227
    IKZF1 degrader, IKZF3 degrader, IRAK-4 degrader
    KT-413
    No biomarker
    TP53 wild-type
    TP53 mutation
    TP53 deletion
    TP53 overexpression
    TP53 mutation + Chr del(17p)
    TP53 A159V
    TP53 expression
    ALK positive
    ALK R214H
    ALK rearrangement
    ALK negative
    ALK I1171N
    ALK C1156Y
    ALK fusion
    MYC rearrangement + BCL2 rearrangement
    MYC overexpression + BCL2 overexpression
    BCL2 overexpression + MYC overexpression
    MYC translocation + BCL2 translocation
    BCL2 expression + MYC expression
    MYC expression + BCL2 expression
    MYC positive + BCL2 positive
    BCL2 rearrangement + MYC amplification
    CD20 positive
    CD20 expression
    CD20 overexpression
    CD20 negative
    CD20 underexpression
    MYC rearrangement + BCL2 rearrangement + BCL6 rearrangement
    CXCR4 mutation
    CXCR4 T318fs*
    MYC positive + BCL2 positive + BCL6 positive
    CXCR4 L326fs*
    CXCR4 G336X
    CXCR4 S347fs*
    MYC translocation + BCL6 translocation + BCL2 translocation
    CXCR4 S338X
    CXCR4 K327fs*
    CXCR4 R338X
    MYC expression + BCL2 expression + BCL6 expression
    CXCR4 H350fs*
    MYC rearrangement + BCL6 rearrangement
    MYC translocation + BCL6 translocation
    TNFRSF8 positive
    PD-L1 overexpression
    PD-L1 expression
    MYC rearrangement
    TNFRSF8 expression
    TNFRSF8 negative
    MYC expression + MYC rearrangement
    MYC positive
    PD-L1 underexpression
    MYC translocation
    MYC negative
    MYC expression
    TNFRSF8 overexpression
    PD-L1 amplification
    MYC mutation
    MYC overexpression
    PD-L1 elevation
    CD19 positive
    CD19 underexpression
    CD19 expression
    CD19 mutation
    BCL2 overexpression
    BCL2 positive
    BCL2 mutation
    BCL2 expression
    BCL2 F104I
    BCL2 amplification
    BCL2 rearrangement
    MYD88 L265P
    MYD88 mutation
    MYD88 wild-type
    LDH elevation
    TMB-L
    BRAF V600
    TMB-H
    BRAF V600E
    LDH-L
    CD20 positive + TMB-L
    IGH mutation
    ABCB1 2677G>T/W
    BIRC3 mutation
    VEGFA 2055A>C
    CCR7 positive
    ABCB1 mutation + VEGFA mutation
    BCL6 translocation
    BCL6 rearrangement
    BCL6 positive
    CCR7 overexpression
    VEGFA 1154G/A
    IGH translocation
    CD38 expression
    CCR4 overexpression
    PD-1 overexpression
    RHOA G17V
    NPM1-ALK fusion
    IL2RA expression
    CCL19 elevation
    CD79B mutation
    MYD88 L265P + CD79B mutation
    CD79B mutation
    IL2RA-L
    KIR3DL2 C336R
    CCR4 positive
    PD-1 underexpression
    PIM1 mutation
    CCL19 overexpression
    RHOA mutation
    Chr t(2;5)(p23;q35) NPM1/ALK
    PIM1 overexpression
    CXCL12 expression
    CXCL12 overexpression
    MYD88 mutation + CD79B mutation
    KIR3DL2 Q386E
    NPM1-ALK I1171N
    IL2RA positive
    PD-1 elevation
    NPM1-ALK F1174C
    CD38 positive
    NPM1-ALK L1196Q
    NPM1-ALK I1171T
    CD79B expression
    NPM-ALK fusion
    IL2RA elevation
    FGFR1 rearrangement + Chr t(8;13)
    CREBBP mutation
    TIGIT overexpression
    HAVCR2 expression
    CD24 overexpression
    RGL1 overexpression
    CD70 expression
    BTK C481
    MYD88 mutation + CXCR4 mutation
    DNMT3A mutation
    CASP3 overexpression + BCL2 negative
    CASP3 overexpression
    NPM1-NR4A3 fusion
    SEPTIN6-TRIM33 fusion
    IDH2 mutation
    CD79A mutation
    EZH2 mutation + BCL2 translocation
    BCL6 fusion + NOTCH2 mutation
    PAX5 overexpression
    TBX21 overexpression
    FOXP1 overexpression
    PD-L1 amplification + LAG3 overexpression
    PD-L1 amplification + HLA-DRA overexpression
    PD-L1 amplification + CD3D overexpression
    MYD88 mutation + PRDM15 expression
    MYD88 mutation + TNIK expression
    MYD88 mutation + GPER1 expression
    MYD88 mutation + DUSP22 expression
    MYD88 mutation + WNK2 expression
    MRD4 negative
    ICOS underexpression
    RPS6 underexpression
    ITK overexpression
    CTLA4 overexpression
    SOX11 expression
    HES1 overexpression
    LMO2 overexpression
    CD19 expression + TNFRSF17 expression
    IL10-L
    TNFA-L
    CCL20-L
    ATM mutation
    MME negative
    CD37 expression
    CCND2 overexpression
    VAV1 mutation
    LAG3 overexpression
    CDCA2 overexpression
    ALK expression + PDGFRA expression
    ALK expression + PDGFRB expression
    FCGR2A mutation
    LRP1B mutation
    H1-4 overexpression
    TP53 T175H + PIK3CA H1047R
    MYD88 L265P + BRAF V600E
    CLTC-ALK fusion
    TP53 mutation + MET amplification + PD-L1 overexpression
    NOTCH2 mutation + NCOA4 mutation + PTEN mutation + EPHA3 mutation + KMT2D mutation
    TSC2 mutation
    CCDC88C-PDGFRB fusion
    IKZF1 deletion + IKZF3 deletion
    IFNG-L
    BCR-ABL1 T315I
    MYC amplification + BCL2 amplification + TNFRSF8 expression
    BIRC3-MALT1 fusion
    IL2-L
    CD20 expression + TNFRSF8 overexpression
    EZH2 mutation
    SOCS1 mutation
    TP53 mutation + CARD11 mutation + SMARCA4 mutation
    CD20 expression + PAX5 expression + BCL2 expression
    CD34 underexpression
    TP63 rearrangement
    CD20 positive + MME positive + TNFRSF8 negative
    GNA12 mutation
    CTSS Y132D
    GNA13 mutation
    EP300 mutation
    CXCR4 S338X + TP53 R196X
    CD14 overexpression
    CD163 overexpression
    ABCC2 underexpression
    KLHL14 mutation
    LEF1 overexpression
    BTLA overexpression
    CRTAM overexpression
    CD22 positive
    BIRC5 expression
    CCND1 overexpression
    EZH2 W113C
    EP300 overexpression
    IL10 elevation
    EZH2 overexpression
    PAX5 mutation
    BTK C481S
    CD163 elevation
    CD70 overexpression
    BIRC3‐MALT1 fusion
    Chr t(2;17)(p23;q23) CLTC/ALK
    ATM underexpression
    CCND1 expression
    EZH2 A682G
    EZH2 Y646F
    CASP3 underexpression + BCL2 positive
    TBX21 expression
    BCL2 fusion + EZH2 mutation
    EZH2 Y641
    TNFA elevation
    IL2 elevation
    MYD88 L265P + CXCR4 mutation
    ATM deletion
    Chr del(17p)
    Chr del(11q)
    CD5 gene expression signature
    Chr amplification(9)(p24.1)
    Chr del(17)(p13.1)
    Chr t(11;14)
    Chr del(11)(q22.3)
    Chr del(6q)(q15)
    IFNG gene signature overexpression
    MHC-II expression
    CCL4 elevation
    KRAS G12A
    CARD11 mutation
    CXCL8 elevation
    TNFSF13B negative
    CD40L negative
    CD79B mutation + TNFAIP3 mutation
    IL6 elevation
    TET2 mutation
    BCL2 overexpression + MCL1 overexpression
    BCL2 overexpression + MCL1 expression
    NCOR1 overexpression
    KMT2D mutation
    IRF8 mutation
    CHD8 overexpression
    MYC expression + MCL1 expression
    BCL2 elevation + IGH elevation
    miR-1244 overexpression + miR-193-5p overexpression
    ARID1B overexpression
    CXCR5 overexpression
    SRC overexpression
    JAK2 overexpression
    LCK overexpression
    B2M mutation
    SETD5 overexpression
    LY9 expression
    miR-6840-3p expression
    CCDC86 expression + NPM1 expression
    BACH2 overexpression
    miR-1244 expression
    PLK4 expression
    PIK3CG expression
    PIK3CD expression
    PIK3CB expression
    PIK3CA expression
    SLC1A5 overexpression
    MALT1 overexpression
    MCL1 overexpression
    ALK negative + TP53 deletion
    BCL2L1 overexpression
    BCL2L11 deletion
    MCL1 expression
    CD58 mutation
    IKZF3 G152A overexpression
    IKZF1 G151A overexpression
    CD28 overexpression
    KLRG1 expression
    SMARCA4 overexpression
    MELK overexpression
    KLHL6 expression
    CCND1 expression + CDK4 expression
    BTK expression + MYC expression
    BTK expression + BCL2 expression + MYC expression
    BTK expression + BCL2 expression
    TERT amplification
    CDK2 amplification
    CDK4 amplification
    MDM2 amplification
    NOTCH1 mutation
    CXCL11 elevation
    AP2M1 overexpression
    NOTCH2 mutation
    NLRC5 mutation
    CD28 expression
    XPO1 E571K
    TP53 mutation + BCL2 rearrangement
    CELF2 mutation
    CHD8 mutation
    miR-17-HG overexpression + MYC positive
    miR-17-HG expression + MYC positive
    miR-17-HG deletion + MYC positive
    SAMHD1 mutation
    CDKN2A deletion + MTAP deletion
    PRMT5 overexpression + MTAP deletion
    DLGAP2 deletion
    MYC rearrangement + LDH elevation
    miR-182-5p expression
    Albumin-L
    CD5 overexpression
    TNFRSF14 mutation
    miR-20b-5p expression
    PRDM1 mutation
    TP53 overexpression + CD5 overexpression
    miR-1231 expression
    FTL elevation
    BCL2 positive + LGALS3 expression
    CDKN2A deletion
    MAD2L2 overexpression
    PDK4 overexpression
    NRAS G13D
    IRF4 mutation
    SLAMF6 expression
    TNFRSF17 expression
    BTG1 mutation
    ETV6 mutation
    REL overexpression
    MUC20 underexpression
    FCGR2B expression
    CDKN2A overexpression
    RB1 deletion
    BRCA mutation
    PPM1D mutation
    HRD
    PAK1 overexpression
    CDKN2B deletion
    CD5 positive
    TNFAIP3 mutation
    MYC expression + PAICS expression
    ROR1 overexpression
    ARID1A mutation
    miR-885-3p expression
    miR-199a-5p expression
    miR-193b-5p expression
    miR-6860-5p expression
    IL27 elevation
    TP53 mutation + ARID1A mutation
    PLCG2 mutation
    LDH elevation + TP53 mutation
    ARID1B deletion
    CD19 positive + CD20 positive
    SETD1B overexpression
    PTPN6 negative
    BCL7A mutation
    ARID1B mutation
    FAS mutation
    SETD2 overexpression
    INO80 overexpression
    PTEN deletion + BCL2 translocation
    KMT2C overexpression
    CD123 positive
    miR-155 overexpression
    BCL2L2 overexpression
    ROR1 expression